Yuanxin HuiBao and OrigiMed Announce Strategic Collaboration to Launch Innovative 'NGS Tumor Testing + Disease & Medication Management' Service

On July 24, 2019, Shanghai Yuanxin Huibao Network Technology Co., Ltd. (hereinafter referred to as “Yuanxin Huibao”) announced that it had entered into a strategic cooperation agreement with OrigiMed INC (hereinafter referred to as “OrigiMed”). Under the agreement, the two parties will jointly develop innovative services integrating “NGS-based tumor testing with disease and medication management.”

This collaboration marks a solid commitment by both parties to advance multi-faceted, in-depth cooperation. By combining Yuanxin Huibao’s strengths in developing insurance products for critical and chronic diseases with OrigiMed’s expertise in international high-tech R&D and the clinical translation of oncology innovations, the partners aim to create premium products that embody the future trends of the industry.

Following the signing of this agreement, both parties will refine core user needs within the existing health market and strive to build an innovative service model centered on “NGS-based tumor testing + disease and medication management.” As the first domestic clinical NGS company to integrate commercial insurance into payment for genetic testing, OrigiMed INC will provide hundreds of cancer-related gene tests to Yuanxin Huibao’s health insurance policyholders after claim settlement. Leveraging Yuanxin Huibao’s service delivery capabilities in “online consultation, medication services, and post-diagnosis management,” along with its professional product integration and design expertise, the partnership will offer insurers the most competitive service pricing and support the design of superior insurance products. This enables users to truly benefit from precise services delivered through professional genetic testing and post-diagnosis management, thereby enhancing the rationality, effectiveness, and timeliness of these services.

OrigiMed focuses on the research and development of international high-tech solutions and their clinical translation in oncology, striving to advance the clinical testing of hundreds of cancer genes. By providing comprehensive and accurate molecular-level information for every patient, OrigiMed assists physicians in delivering precision therapy and drives innovation in the clinical treatment of cancer patients in China. OrigiMed offers four strictly validated series of tumor gene testing products and is the first precision medicine company in China to provide comprehensive tumor molecular profiling. It pioneered “Dr. Marmot,” an app for precision treatment data sharing and patient follow-up. Its service network covers more than 300 core hospitals across five major regions in China. OrigiMed has obtained clinical laboratory qualifications issued by the National Health and Family Planning Commission of China, as well as official accreditation from the College of American Pathologists (CAP) and certification under the Clinical Laboratory Improvement Amendments (CLIA).

Yuanxin Huibao is a health insurance technology company specializing in post-policy services for health insurance. Focusing on insurance products covering critical illnesses, chronic diseases, and other health-related areas, it delivers more reliable medical and pharmaceutical services to users while providing insurers with solutions in “actuarial pricing, risk control, customer acquisition, and retention.” Yuanxin Huibao has established in-depth collaborations with numerous healthcare companies. It possesses service delivery capabilities in “genetic screening, health check-ups, overseas medical care, online consultations, medication services, and post-diagnosis management.” By addressing core user needs in the current market and leveraging its professional product integration and design expertise, the company offers insurers optimal service pricing, supports the development of higher-quality insurance products, and ensures that users truly benefit from reasonable services and effective medical coverage.